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Background: The prognostic impact of segmental chromosome alterations (SCAs) in children older than 1 year, diagnosed with
localised unresectable neuroblastoma (NB) without MYCN amplification enrolled in the European Unresectable Neuroblastoma
(EUNB) protocol is still to be clarified, while, for other group of patients, the presence of SCAs is associated with poor prognosis.
Methods: To understand the role of SCAs we performed multilocus/pangenomic analysis of 98 tumour samples from patients
enrolled in the EUNB protocol.
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Results: Age at diagnosis was categorised into two groups using 18 months as the age cutoff. Significant difference in the
presence of SCAs was seen in tumours of patients between 12 and 18 months and over 18 months of age at diagnosis, respectively
(P¼ 0.04). A significant correlation (P¼ 0.03) was observed between number of SCAs per tumour and age. Event-free (EFS) and
overall survival (OS) were calculated in both age groups, according to both the presence and number of SCAs. In older patients, a
poorer survival was associated with the presence of SCAs (EFS¼ 46% vs 75%, P¼ 0.023; OS¼ 66.8% vs 100%, P¼ 0.003). Moreover,
OS of older patients inversely correlated with number of SCAs (P¼ 0.002). Finally, SCAs provided additional prognostic
information beyond histoprognosis, as their presence was associated with poorer OS in patients over 18 months with unfavourable
International Neuroblastoma Pathology Classification (INPC) histopathology (P¼ 0.018).
Conclusions: The presence of SCAs is a negative prognostic marker that impairs outcome of patients over the age of 18 months
with localised unresectable NB without MYCN amplification, especially when more than one SCA is present. Moreover, in older
patients with unfavourable INPC tumour histoprognosis, the presence of SCAs significantly affects OS.
Peripheral neuroblastic tumours are a heterogeneous group of
cancers with regard to clinical, genetic and histopathological
classification, the most frequent being neuroblastoma (NB). Stage
and age at diagnosis are important prognostic clinical features
(Breslow and McCann, 1971; London et al, 2005a,b; Deyell and
Attiyeh, 2011), but disease outcome is also strongly influenced by
the presence of genomic alterations in neuroblastic cells, for
example, amplification of the MYCN oncogene, a powerful
prognostic marker that occurs in about 20% of the patients
(Brodeur et al, 1984; Seeger et al, 1985; Sansone et al, 1991; Tonini
et al, 1997, 2012).
Segmental chromosome alterations (SCAs) other than MYCN
amplification have been described as associated with tumour
aggressiveness (Janoueix-Lerosey et al, 2009; Schleiermacher et al,
2010; Coco et al, 2012). Janoueix-Lerosey et al (2010) suggested a risk
criteria assessment based on five classes of genomic alterations,
ranging from tumours with only numerical alterations and the
absence of disease-related deaths, to tumours with MYCN
amplification and SCAs in patients with a poor outcome (Ambros
et al, 2009; Janoueix-Lerosey et al, 2009). On the basis of these
observations, the ‘multilocus’ (i.e., Multiplex Ligation Probe
Amplification) or ‘pangenomic’ (i.e., array-based) approach to define
tumour genomic profile for therapeutic stratification is a potential
important tool to guide therapy (Janoueix-Lerosey et al, 2009).
In 2001, the SIOPEN (International Society of Paediatric
Oncology European Neuroblastoma) launched the European
Unresectable Neuroblastoma (EUNB) study for the treatment of
children over 1 year of age with localised unresectable NB, defined by
the presence of surgical risk factors (SRFs) and without MYCN
amplification. Clinical results of the study have already been
published elsewhere (Kohler et al, 2013). After early biopsy,
chemotherapy was the initial approach for this group of patients
followed, when possible, by delayed surgery. As these patients did not
undergo tumour resection at diagnosis, an accurate characterisation
of the biological features of the tumour to detect genetic alterations of
prognostic significance following tumour biopsy, was of the upmost
importance. On the basis of these considerations, we have analysed
tumours from these patients to detect the presence of SCAs and their
potential influence on survival in this uniformly treated cohort.
PATIENTS AND METHODS
Patients. Between January 2001 and October 2006, 160 patients
from 10 different European countries (Austria, Belgium, Czech
Republic, France, Italy, Norway, Portugal, Spain, Sweden, and
United Kingdom) were enrolled in the EUNB protocol with a new
diagnosis of localised unresectable NB, as defined by the presence
of SRFs. Informed consent was obtained from patients’ parents or
guardians. A pangenomic/multilocus approach was possible for
tumour samples from 98 patients.
Tumour samples. Tumours samples at diagnosis were centrally
collected at the national reference centres and processed according
to the standard procedures of the SIOPEN Biology European
Neuroblastoma Quality Assessment (ENQUA) Group (Ambros
et al, 2001). Only samples with X60% of neuroblastic cells were
considered for array CGH and Multiplex Ligation Probe
Amplification (MLPA) analysis.
Multiplex Ligation Probe Amplification. The MLPA (SALSA
MLPA kit p251/A1-B1, p252/A1-B1, p253/A1-B1 neuroblastoma,
MRC Holland, Amsterdam, The Netherlands) was performed on
DNA samples as previously described (Ambros et al, 2011). The
neuroblastoma MLPA kits are designed to assess the status of
selected regions in the following chromosomes: 1, 2, 3, 4, 7, 9, 11,
12, 14, and 17.
Array CGH. Following standardised extraction, 30 DNA samples
were analysed by array CGH using an in-house BAC/PAC array
with a genomic resolution of B1Mb, as reported previously
(Janoueix-Lerosey et al, 2009, 2010) and 9 by a commercially
available NimbleGen DNA array (Roche NimbleGen, Madison,
WI, USA) containing 72 000 oligonucleotide probes with an
average resolution of B1 probe per 40 kb.
Nomenclature of SCAs. The presence and number of SCAs
frequently occurring in NB (see Results) were classified according to
the SIOPEN Biology guidelines (Ambros et al, 2011). No SCA is
indicated by the code s0, where ‘s’ stands for ‘segmental’. In the cases
of SCAs, the code indicates the number of SCAs (s1, s2, s3, and so
on). The presence of an unbalanced ratio between the signals of
chromosomal regions of interest (decreased/increased mean value of
more than 0.25 of at least two adjacent probes as compared with the
mean values of the remaining probes of the concerned chromosome/
chromosomal arm) and the reference signals defined a SCA by
MLPA (Ambros et al, 2011). Segmental chromosome alterations
identified by array CGH were defined by the presence of either at
least 3 adjoining BAC/PAC clones or 100 contiguous oligonucleotide
probes showing a genomic status different from that of the rest of
the chromosome (Schleiermacher et al, 2011).
Statistical analysis. Age at diagnosis was categorised into two
groups using 18 months as age cutoff. Disease progression, relapse,
and death were considered as events. Event-free (EFS) and overall
survival (OS) were estimated by the Kaplan–Meier method and
differences between groups were assessed by the log-rank test.
Survival estimates referred to 5 years from diagnosis and the
related 95% confidence intervals (95% CIs) were calculated by the
Kalbfleisch and Prentice method (Kalbfleisch and Prentice, 1980).
All statistical tests were two-sided and a P-value of o0.05 was
considered as significant. All analyses were performed using the
statistical package ‘Stata’ (release 11.0, Stata Corporation, College
Station, TX, USA).
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RESULTS
A multilocus/pangenomic approach was possible for 98 out of 160
(61.2%) patients enrolled in the EUNB study. For the remaining 62
patients, there was insufficient tumour available for genetic studies
or samples contained a low percentage of neoplastic cells. Of the 98
patients, 38 (38.8%) were 12–18 months of age at diagnosis and 60
(61.2%) were older than 18 months. Centrally reviewed INPC
(International Neuroblastoma Pathology Classification) classifica-
tion assessed by the pathology panel was available for 68 out of 98
patients (69.4%), of whom 28 (21 were 12–18 months and 7 over
18 months at diagnosis) had favourable and 40 (5 were 12–18
months and 35 over 18 months at diagnosis) unfavourable
histoprognosis. To exclude any selection bias, the 98 patients were
compared with the 62 not studied by multilocus/pangenomic
approach, with regard to age, sex, stage, country of origin, tumour
site, type of biopsy, relapses, deaths, and INPC (Shimada et al,
1999). No significant differences were observed between the two
groups (Supplementary Table 1; Supplementary Figure 1).
The MLPA and array CGH techniques were used to study 59
and 39 tumour samples, respectively. High intertechnique
concordance has been previously described by Ambros et al
(2011). All data were centrally reviewed by the ENQUA Biology
group. The current study is a separate cohort from that previously
studied by Ambros et al (2011) and Schleirmacher et al (2011).
Since MLPA gave results on the status of selected genetic loci of
specific chromosomes while array CGH allowed the evaluation of all
the chromosomes, combined results of the two techniques were
reported only for those regions included in the MLPA kit. Forty-four
tumours (44.9%) did not show any SCA (s0). In 54 tumours (55.1%)
the multilocus/pangenomic approach showed at least 1 SCA out of
the 7 mostly recurrent in NB, namely gain of 1q, 2p, 17q and loss of
1p, 3p, 4p, 11q. The following SCAs, listed by frequency, were
observed: 17q gain (35%; 34 out of 97), 1p loss/1q gain (26%; 24 out
of 93), 11q loss (25%; 24 out of 96), 2p gain (17.5%; 17 out of 97), 3p
loss (7%; 7 out of 96), and 4p loss (4%; 4 out of 97). Among the other
chromosomes included in the MLPA kit, we detected gain of 7q in
10% of samples (10 out of 98), 12q gain in 4% (4 out of 98), and 14q
loss in 3% (3 out of 97). Among the chromosomes analysed by aCGH
only, a deletion of 6q was seen in 10% of the tumour samples (4 out of
39). With respect to the number of SCAs, 21 tumours (38.9%) were
classified as s1, 17 (31.5%) as s2, 10 (18.5%) as s3, and 6 (11.1%) as s4.
Henceforth when reporting information on SCAs, we will refer
only to the seven recurrent SCAs in NB reported above, detected
either by MLPA or by array CGH.
Since age at diagnosis has an important role in patient risk
assessment, as reported by Kohler et al (2013), we stratified
patients by 18 months age cutoff. The percentage of tumours with
at least 1 of the 7 recurrent SCAs in NB was significantly greater in
the 60 patients older than 18 months of age compared with the 38
ones 12–18 months old (63% vs 42%; P¼ 0.04).
Moreover, the number of SCAs per tumours (i.e., no SCA, 1
SCA or more than 1 SCA) significantly correlated with age at
diagnosis, as only 1 of 38 patients aged less than 18 months (2.6%)
had more than two SCAs, while 15 of 60 older patients (25%)
showed more than two SCAs (P¼ 0.031) (Figure 1).
Overall and event-free survival were calculated for both age groups
according to the presence of SCAs. For children aged 12–18 months,
the presence of SCAs did not influence survival (OS 100% vs 100%,
EFS 100% vs 95.5%, P¼ 0.45). In particular, 22 patients with tumours
without SCAs experienced two events and only one event occurred in
the 16 patients with tumours with SCAs (data not shown).
For children older than 18 months at diagnosis, the presence of
SCAs was significantly associated with OS (100% children without
SCAs vs 66.8% childrenX1 SCA, P¼ 0.003) (Figure 2A) and with
EFS (75% vs 46.1%, P¼ 0.023) (Figure 2B).
The prognostic significance of each of the seven recurrent SCAs
with respect to both OS and EFS has been evaluated before and
after age stratification. Results for the whole cohort and for
children over 18 months of age are reported in Table 1. There was
a significant correlation between all the SCAs, but for 3p loss, and
OS, without any differences according to age stratification, except
for 11q loss (Table 1). Event-free survival did correlate with 4p loss,
11q loss and 17q gain in the whole cohort, without any differences
according to age stratification. Results for the group 12–18 months
were not statistically significant (Supplementary Table 2).
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Figure 1. Distribution of the number of SCAs in tumours of patients
under and over 18 months of age at diagnosis. On the left side the
number of tumours without (s0) or with (s1, s2, s3, s4) SCAs in patients
less than 18 months at diagnosis, on the right side the number of
tumours without (s0) or with (s1, s2, s3, s4) SCAs in patients over 18
months. The graph shows that tumours of older patients have increased
number of SCAs, in particular three or more SCAs per tumour.
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Figure 2. Kaplan–Meier survival analysis showing 5-year OS (A) and
EFS (B) in patients over than 18 months of age at diagnosis according
to the presence SCAs. Presence of SCAs refers to the seven most
common SCAs observed in neuroblastoma (1p , þ 1q, þ2p, 3p ,
4p, 11q , þ 17q). (A) OS was 100% in the absence of SCA and 66.8%
in the presence of SCAs; (B) EFS was 75% in the absence of SCAs and
46.1% in the presence of SCAs.
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We further calculated OS and EFS according to the number of
SCAs in the two groups based on the age at diagnosis. There was
no significant correlation between EFS and number of SCAs in
both groups (Supplementary Figure 2). Overall survival was
significantly associated with the number of SCAs in patients over
18 months of age (OS 100% vs 84.6% vs 57.9%, P¼ 0.002)
(Figure 3). We also studied the impact of SCAs in patients with
both favourable and unfavourable histoprognosis. A statistically
significant association between a poor OS and the presence of
SCAs (OS 100% vs 61%, P¼ 0.0183) (Figure 4A) was observed in
patients over 18 months with unfavourable histoprognosis, while
EFS was not influenced (Figure 4B).
DISCUSSION
Patients enrolled in the EUNB protocol represent a cohort of
patients whose tumours have normal MYCN gene status, suitable to
be investigated for the presence of SCAs and their role in disease
outcome. In this study, the genomic pattern of the tumour cells was
analysed by multilocus/pangenomic assays with the aim to identify
possible correlations between chromosome abnormalities other than
MYCN amplification and the occurrence of adverse disease events.
MYCN gene amplification, described in about 20% of NB, is one
of the most reliable prognostic markers and is used to determine
treatment in infants and in children with localised disease. In
patients whose tumour lacks MYCN amplification, the poor
prognosis could be associated with the presence of other SCAs.
This indicates that SCAs have an important role in disease
progression and their presence is a useful prognostic marker in NB.
Age at diagnosis was categorised into two groups by 18 months as
age cutoff (12–18 and more than 18 months) to verify whether the
SCAs correlated with age. The presence of SCAs differed significantly
in the two patient groups and, in addition, tumours of older children
had a significantly higher number of SCAs compared with those of
the younger ones, confirming previous results (Schleiermacher et al,
2010; Coco et al, 2012; Stigliani et al, 2012). Regarding the impact of
SCAs on disease course, we observed a significant correlation between
Table 1. Five-year overall survival (OS) and event-free survival (EFS) of the 98 patients whose tumours were analysed by
multilocus/pangenomic approach, according to the presence of segmental chromosome aberrations (SCAs) and age at diagnosis
SCAs
No. of
tumours with
SCA OS (%)
95%
Confidence
interval P EFS (%)
95%
Confidence
interval P
1p 0.014 0.904
No 75 92.7 83.2–96.9 73.6 61.7–82.4
Yes 18 70.0 41.5–86.5 72.2 45.6–87.4
1p age 418months 0.004 0.487
No 46 88.3 74.1–95.0 59.2 43.1–72.2
Yes 11 47.7 14.1–75.7 54.6 22.9–78.0
þ 1q 0.001 0.192
No 87 90.7 81.1–95.5 75.0 64.1–83.0
Yes 6 50.0 11.1–80.4 50.0 11.1–80.4
þ 1q age 418months 0.005 0.389
No 52 84.3 69.3–92.4 59.9 44.6–72.1
Yes 5 40.0 5.2–75.3 40.0 5.2–75.3
þ 2p 0.014 0.064
No 80 90.8 80.3–95.8 76.6 65.2–84.6
Yes 17 70.6 43.2–86.6 52.9 27.6–73.0
þ 2p age 418months 0.027 0.089
No 47 84.5 68.1–92.9 62.2 46.1–74.7
Yes 13 61.5 30.8–81.8 38.5 14.1–62.8
3p 0.301 0.083
No 89 87.9 78.5–93.3 75.6 64.9–83.4
Yes 7 83.3 27.3–97.5 42.9 9.8–73.4
3p age 418months 0.811 0.427
No 52 79.4 64.9–88.4 59.9 44.6–72.1
Yes 7 83.3 27.3–97.5 42.9 9.8–73.4
4p o0.001 0.042
No 93 89.1 79.8–94.2 75.5 65.1–83.2
Yes 4 50.0 5.8–84.5 25.0 0.9–66.5
4p age 418months 0.016 0.260
No 55 81.6 67.1–90.2 60.3 45.6–72.2
Yes 4 50.0 5.8–84.5 25.0 0.9–66.5
11q 0.035 0.035
No 72 93.0 84.0–97.0 79.6 67.7–87.5
Yes 24 77.8 54.4–90.2 58.3 36.5–75.0
11q age 418months 0.074 0.101
No 41 87.6 72.8–94.7 66.5 48.9–79.2
Yes 17 67.4 37.9–85.2 41.2 18.6–62.6
þ 17q 0.002 0.050
No 63 94.0 81.6–98.1 78.3 65.1–86.9
Yes 34 74.5 55.2–86.5 60.9 42.4–75.1
þ 17q age 418months 0.009 0.211
No 34 89.2 68.9–96.5 62.8 43.2–77.3
Yes 26 65.4 41.8–81.3 48.5 28.2–66.1
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poor prognosis in older children and both the presence and number
of SCAs, irrespective of the chromosome involved. This observation
indicates that the presence of any SCA, in particular more than one,
rather than a specific SCA, affects the disease course. Essentially, in
the cohort of 98 patients, as well as in the older subgroup, all types of
SCAs, except 3p loss, were associated with a poor OS and in the older
group, statistical significance for 11q loss was borderline. Chromo-
some 11q loss was significantly associated with worse OS and EFS
(both P¼ 0.035) in the whole cohort of patients. Loss of 11q, a
negative prognostic factor that is usually inversely associated with
MYCN amplification (Fisher et al, 2010), was detected in 25% of cases,
mostly in patients over 18 months of age at diagnosis (namely, 7 out
of 38 under and 17 out of 60 over 18 months, respectively). It has
been suggested that 11q loss is associated with a poor prognosis in
older children (Care´n et al, 2010). Our results indicate that neither
MYCN amplification nor 11q deletion are the unique chromosome
defects associated with NB progression but rather accumulation of
diverse SCAs have a critical impact in tumour progression.
Taking into account the results of array CGH alone, we
observed 6q loss in 4 out of 39 (10%) patients, 3 of whom were
older than 18 months. Our observation is in accordance with
previous results from Stallings et al (2006), who reported 8% of 6q
loss in a subset of 49 NB. Michels et al (2007) showed 6q loss in
55% of NB cell lines and in 2 out of 75 (3%) primary tumours.
Although chromosome 6 is frequently involved in other malig-
nancies, (Mitelman et al) 6q loss is a rare event in NB (Michels
et al, 2007). Patients older than 18 months of age, whose tumour
shows 6q loss, had significant poor EFS (P¼ 0.046, data not
shown) compared with those without, but we think that the
number of cases is too small to draw any conclusion.
Data reported by Kohler et al (2013) regarding the clinical course
of patients enrolled in the EUNB study showed that the group of
patients with unfavourable tumour histoprognosis and older age had
a worse outcome, suggesting that more intensive treatment for this
group of patients is needed. On the basis of these data, we studied
the potential significance of the presence of SCAs in the subgroup of
patients with INPC unfavourable tumour histoprognosis. Of note, a
statistically significant correlation between a poor OS and the
presence of SCAs was observed in patients over 18 months. Event-
free survival was not influenced by SCAs, as a similar number of
events occurred in patients of both groups of age.
Overall, our data show that both the presence and number of
SCAs are associated with older age and represent a poor prognostic
marker for patients over 18 months of age at diagnosis, with localised
unresectable MYCN non-amplified NB. Moreover, older patients
with INPC unfavourable tumour histoprognosis, whose tumours do
not present SCAs, are more likely to survive after relapse than
patients with tumour with SCAs. Future clinical trials of this group of
patients should be stratified by the presence and number of SCAs.
In conclusion, this study shows an example of tumour molecular
analysis in an homogenous group of unresectable NB patients
enrolled in a unique clinical trial. Although it was not possible to
collect tumour samples from all patients, the homogeneity of the
records made up for this lack. Our study also indicates that close
cooperation among oncologists, surgeries, pathologists, and biolo-
gists is mandatory to recover as many biological samples as possible
and to give to the patient the best diagnosis and treatment. In the
future, this close cooperation should be strengthened, together with
a more standardisation of the molecular approaches.
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